About This Page
This is a clinician-written, evidence-based summary aligned to the USMLE Step 2 CK Content Outline. It is intended for medical students preparing for USMLE Step 2 CK. Management reflects current ACC/AHA, USPSTF, and APA guidelines. Always cross-reference with UpToDate, institutional protocols, and clinical judgment.
Key points
- Most cervical cancer is caused by persistent high-risk HPV, especially HPV 16 and 18
- Screening begins at age 21 in ACOG/USPSTF-aligned guidance; ACS favors primary HPV testing from age 25 when available
- Age 21-29: cytology every 3 years in ACOG/USPSTF-aligned guidance
- Age 30-65: cytology every 3 years, primary HPV every 5 years, or cotesting every 5 years
- Abnormal screening is managed by risk-based algorithms using HPV status, cytology, prior results, and CIN history
Overview
Cervical cancer arises from premalignant cervical intraepithelial neoplasia caused by persistent oncogenic HPV infection at the transformation zone. Screening detects precancer before invasive disease develops; vaccination prevents infection with high-risk types.
Epidemiology
Incidence and mortality have declined substantially due to screening. Risk factors include persistent high-risk HPV, early sexual activity, multiple partners, immunosuppression, smoking, lack of screening, DES exposure, and low access to preventive care.
Clinical Features
Symptoms
Precancer and early cancer often asymptomatic
Postcoital bleeding is classic
Intermenstrual or postmenopausal bleeding
Watery, bloody, or foul discharge
Pelvic pain, leg swelling, urinary obstruction, or weight loss suggests advanced disease
Signs
Friable cervical lesion, ulcer, mass, or contact bleeding
Normal exam common in screen-detected precancer
Cervical motion tenderness suggests cervicitis/PID
Parametrial involvement or fixed mass suggests advanced disease
Genital warts are usually low-risk HPV and do not equal cancer
Investigations
First-line
Cervical cytology and/or HPV testingScreening modality depends on age and pathway
Colposcopy with biopsyDiagnostic for abnormal screening or suspicious lesion
Pregnancy testBefore procedures and in reproductive-age bleeding evaluation
Second-line
Endocervical samplingSelected colposcopy scenarios depending on age, pregnancy, cytology, visualization
Excisional procedureLEEP or cone for high-grade lesions or suspected microinvasion
Staging workupFor invasive cancer: pelvic exam and imaging as indicated
Specialist
Gynecologic oncology referralInvasive cancer, suspected malignancy, or complex high-grade disease
ASCCP risk-based managementGuides surveillance vs colposcopy vs treatment
1
Average-risk screening
- Age <21: no screening regardless of sexual activity
- Age 21-29: cervical cytology every 3 years in ACOG/USPSTF-aligned guidance
- Age 30-65: cytology every 3 years, primary high-risk HPV every 5 years, or cotesting every 5 years
- Stop after 65 if adequate prior negative screening and no high-grade history requiring surveillance
- No screening after total hysterectomy for benign indication with cervix removed and no CIN2+ history
2
HPV vaccination
- Routine vaccination ages 11-12, can start age 9
- Catch-up through age 26 if not adequately vaccinated
- Shared decision-making ages 27-45 in selected patients
- Vaccination does not remove need for screening
3
Precancer management
- Low-grade abnormalities often surveillance or colposcopy depending on risk
- CIN2/3 generally requires excisional treatment in nonpregnant patients
- Pregnancy alters timing; suspected invasive cancer needs specialist evaluation
4
Invasive cancer
- Early-stage disease may be surgical or fertility-sparing in selected cases
- Locally advanced disease often chemoradiation
- Gynecologic oncology leads management
Complications
- Invasive cervical cancer: Preventable progression from untreated high-grade CIN
- Hemorrhage or obstruction: Advanced tumors can bleed or cause hydronephrosis/fistulae
- Procedure-related obstetric risk: Cervical excision can increase preterm birth risk
- Psychological distress: Abnormal HPV/Pap results require counseling
- Underscreening: Main driver of preventable cervical cancer
USMLE Step 2 CK Exam Tips
- 1No screening before age 21 in ACOG/USPSTF-aligned testing
- 2Age 21-29: Pap every 3 years
- 3Age 30-65: Pap q3, HPV q5, or cotest q5
- 4Postcoital bleeding + friable lesion = biopsy, not Pap
- 5HPV 16/18 highest risk
- 6ASC-US with positive high-risk HPV generally leads to colposcopy
- 7HPV vaccination does not change screening intervals
- 8Visible suspicious lesion requires biopsy even if recent Pap normal
Put your reading into practice
Topic-specific question practice is not linked for this article yet.
Choose USMLE Step 2 CK questions from the existing bank. General exam practice covers your selected topics; it is not filtered to this article. Your usual question-bank access applies.
Choose USMLE Step 2 CK practiceAfter your session, return to this section to revisit the reading and choose your next review.
Verified Sources & References
related resources
Save your place and choose what comes next
Obstetrics & Gynecology · Article 21 of 24